| Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group A Le Cesne, I Ray-Coquard, F Duffaud, C Chevreau, N Penel, BB Nguyen, ... European Journal of Cancer 51 (6), 742-750, 2015 | 105 | 2015 |
| Management of choroidal metastases P Jardel, W Sauerwein, T Olivier, E Bensoussan, C Maschi, F Lanza, ... Cancer treatment reviews 40 (10), 1119-1128, 2014 | 84 | 2014 |
| Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group AT Falk, L Moureau-Zabotto, M Ouali, N Penel, A Italiano, JO Bay, ... Clinical oncology 27 (1), 48-55, 2015 | 79* | 2015 |
| Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ A Krämer, T Bochtler, C Pauli, G Baciarello, S Delorme, K Hemminki, ... Annals of Oncology 34 (3), 228-246, 2023 | 71 | 2023 |
| Anticancer drugs approved by the US food and drug administration from 2009 to 2020 according to their mechanism of action T Olivier, A Haslam, V Prasad JAMA network open 4 (12), e2138793-e2138793, 2021 | 70 | 2021 |
| 943PLocation of mutation in BRCA2 gene and survival in patients with ovarian cancer SI Labidi-Galy, T Olivier, M Rodrigues, D Ferraioli, O Derbel, A Bodmer, ... Annals of Oncology 28 (suppl_5), 2017 | 51* | 2017 |
| The promise of digital biopsy for the prediction of tumor molecular features and clinical outcomes associated with immunotherapy GL Banna, T Olivier, F Rundo, U Malapelle, F Fraggetta, M Libra, A Addeo Frontiers in medicine 6, 172, 2019 | 49 | 2019 |
| Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? T Olivier, E Fernandez, I Labidi-Galy, PY Dietrich, V Rodriguez-Bravo, ... Cancer treatment reviews 97, 102204, 2021 | 36 | 2021 |
| The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA. T Olivier, V Prasad Translational Oncology 18, 101374, 2022 | 30 | 2022 |
| 1003P Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers SI Labidi-Galy, T de, LM Rouge, O Derbel, A Wolfer, E Kalbacher, ... Annals of Oncology 30 (Supplement_5), mdz250. 011, 2019 | 28* | 2019 |
| Treating metastatic sarcomas locally: a paradoxe, a rationale, an evidence? T Olivier, D Pop, AC Djebaili, AT Falk, A Iannessi, E Saada, W Nettekoven, ... Critical Reviews in Oncology/Hematology 95 (1), 62-77, 2015 | 23 | 2015 |
| Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review L Thouvenin, T Olivier, G Banna, A Addeo, A Friedlaender Therapeutic Advances in Drug Safety 12, 20420986211004745, 2021 | 20 | 2021 |
| The definition of long COVID used in interventional studies A Haslam, T Olivier, V Prasad European Journal of Clinical Investigation 53 (8), e13989, 2023 | 16 | 2023 |
| Association between US drug price and measures of efficacy for oncology drugs approved by the US Food and Drug Administration from 2015 to 2020 MD Miljković, JE Tuia, T Olivier, A Haslam, V Prasad JAMA internal medicine 182 (12), 1319-1320, 2022 | 16 | 2022 |
| Tebentafusp in first-line melanoma trials: An outperforming outlier T Olivier, V Prasad Translational Oncology 20, 101408, 2022 | 16 | 2022 |
| Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials T Olivier, A Haslam, V Prasad Journal of Clinical Epidemiology 139, 80-86, 2021 | 15 | 2021 |
| Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm T Olivier, V Prasad Translational Oncology 15 (1), 101248, 2022 | 14 | 2022 |
| Cost per event averted in cancer trials in the adjuvant setting from 2018 to 2022 I Mousavi, T Olivier, V Prasad JAMA Network Open 5 (6), e2216058-e2216058, 2022 | 13 | 2022 |
| Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer: limitations of the VISION trial T Olivier, K Powell, V Prasad European Urology 84 (1), 4-6, 2023 | 12 | 2023 |
| Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020 T Olivier, A Haslam, V Prasad BMC cancer 23 (1), 448, 2023 | 12 | 2023 |
Isabelle Ray-CoquardCentre Leon Berard & Universite Claude Bernard Lyon I在 lyon.unicancer.fr 的电子邮件经过验证
